These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30286225)

  • 1. Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    Boozalis E; Kwatra SG; Marrone KA
    JAMA Oncol; 2019 Feb; 5(2):261-262. PubMed ID: 30286225
    [No Abstract]   [Full Text] [Related]  

  • 2. Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.
    Trager MH; de Clippelé D; Ram-Wolff C; de Masson A; Vignon-Pennamen MD; Battistella M; Michel L; Bagot M; Dobos G
    Acta Derm Venereol; 2020 May; 100(10):adv00158. PubMed ID: 32449779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
    Fattore D; Panariello L; Annunziata MC; Fabbrocini G
    Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
    [No Abstract]   [Full Text] [Related]  

  • 4. Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate.
    Varma A; Friedlander P; De Moll EH; Desman G; Levitt J
    Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histologically-diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report.
    Kim YE; Kim TM; Jo SJ
    J Dermatol; 2019 Dec; 46(12):e464-e466. PubMed ID: 31531885
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypertrophic lichenoid eruption due to furosemide.
    Arias-Santiago S; Aneiros-Fernandez J; Aceituno-Madera P; Burkhardt-Perez P; Naranjo Sintes R
    Acta Derm Venereol; 2010; 90(1):78-9. PubMed ID: 20107731
    [No Abstract]   [Full Text] [Related]  

  • 7. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
    Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
    Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
    J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
    [No Abstract]   [Full Text] [Related]  

  • 11. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL; Chen KY; Kuo SW; Chang YL
    J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract]   [Full Text] [Related]  

  • 12. Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer.
    Tanaka M; Hoashi T; Ichiyama S; Noro R; Seike M; Kubota K; Gemma A; Funasaka Y; Saeki H
    Australas J Dermatol; 2019 Feb; 60(1):e67-e68. PubMed ID: 29896926
    [No Abstract]   [Full Text] [Related]  

  • 13. Alirocumab-Associated Lichenoid Reaction: A Case Report.
    Román Cheuque R; Navarro-Navarro I; Jiménez-Gallo D; Linares Barrios M
    Actas Dermosifiliogr; 2024 May; 115(5):522-523. PubMed ID: 37848129
    [No Abstract]   [Full Text] [Related]  

  • 14. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
    J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    Romeo MAL; Garassino MC; Moiola L; Galli G; Comi G; Martinelli V; Filippi M
    J Neurol; 2019 Dec; 266(12):3163-3166. PubMed ID: 31586260
    [No Abstract]   [Full Text] [Related]  

  • 16. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
    Coscarart A; Martel J; Lee MP; Wang AR
    J Cutan Pathol; 2020 Mar; 47(3):275-279. PubMed ID: 31589773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
    Freitas C; Sampaio L; Fernandes G
    J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
    [No Abstract]   [Full Text] [Related]  

  • 18. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y; Ishii Y; Oki M
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract]   [Full Text] [Related]  

  • 20. Generalized morphea in the setting of pembrolizumab.
    Cheng MW; Hisaw LD; Bernet L
    Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.